The bill amends Florida Statutes to enhance Medicaid coverage for biomarker testing, particularly in relation to colorectal cancer. It revises the definition of "biomarker testing" to include specific types of analyses and establishes that the Agency for Health Care Administration (AHCA) must create a reimbursement schedule and billing codes for these tests by August 1, 2025. Additionally, the bill mandates that Medicaid managed care plans cover medically necessary blood-based biomarker tests for colorectal cancer screening at the same level as other necessary tests. The bill also requires the AHCA to conduct a comprehensive cost-benefit analysis of these tests, with interim and final reports due by November 2028 and November 2030, respectively.

Furthermore, the bill clarifies that while biomarker testing is not required for screening purposes, the agency may cover medically necessary blood-based tests for colorectal cancer screening. The provisions related to biomarker testing and managed care plans will be repealed on July 1, 2031, unless reenacted by the Legislature. This legislative effort aims to improve access to advanced testing methods that can aid in the early detection and treatment of colorectal cancer, ultimately enhancing patient outcomes within the Medicaid program.

Statutes affected:
H 1335 Filed: 408.9091
H 1335 c1: 409.9745